Abstract

Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)13-14
Number of pages2
JournalNature Reviews Drug Discovery
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Erlotinib hydrochloride'. Together they form a unique fingerprint.

  • Cite this